Implementation of novel techniques to analyze the fluidic signature of phacoemulsification performed using different ultrasound modalities and phaco tips is providing important insights that will be helpful for improving the efficiency and safety of lens removal surgery.
A study reported in the July issue of Ophthalmology, the journal of the American Academy of Ophthalmology correlates the incidence of silent cerebral infarcts (SCI) and visual field loss in patients with normal-tension glaucoma.
A further study in the July issue of Ophthalmology, the journal of the American Academy of Ophthalmology, investigated inflammation biomarkers in relation to corneal transplant rejection in herpes simplex patients. Its results have shown that inflammation thwarts corneal transplants.
Can BAK be used in corneal cross linking?
How hyaluronic acid-based eye drops can help repair nerve damage.
Latest technology for cataract surgery.
Examining how best to treat dry eye in LASIK patients.
How to retain mositure on the ocular surface
A look at the science behind accommodation and how it must be understood properly in order to create effective lenses
Long-term SLT experience
Stem cell technology for AMD treatment
Does gender make a difference to patient satisfaction?
A preview of this year's ESCRS congress in Barcelona.
Ozurdex, the first drug therapy for the treatment of macular oedema, following branch retinal vein occlusion or central retinal vein occlusion, has been approved by the FDA.
High molecular weight increases blink rate and helps eye drops retain moisture on the ocular surface according to Professor Giancarlo Montani an optometrist FIACLE and a professor of optometry at the Universita del Salento in Italy.
Oertli has developed a new phaco tip, easyTip2.2mm, based on the design of the CO-MICS 2. It uses a new fluidics concept with a high vacuum setting and a wide infusion path, creating a strong axially directed flow.
Nerve damage associated ocular dryness improved dramatically with hyaluronic acid-based lubricating eye drops explains Claes Feinbaum M.Sc. Professor Emeritus Optometry, Vision4You, Lund, Sweden.
Ocular applications of gene therapies are increasing, as is our understanding of the molecular pathogenesis of glaucoma.
A biological marker for neovascular age-related macular degeneration (AMD) has been discovered by a team of researchers from the University of Kentucky.
A new suite of optical coherence tomography (OCT) software applications for the Cirrus HD-OCT has been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution.
Dr Jayakrishna Ambati, professor and vice chairman of Ophthalmology and Visual Sciences at the University of Kentucky, has been chosen to receive the 2010 Cogan Award from The Association for Research in Vision and Opthalmology (ARVO).
The twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study investigating the efficacy and safety of combining Visudyne (Novartis Pharma AG) and Lucentis (Novartis Pharma AG, Genentech Inc.) have been released and so far are showing no significant differences.
Producing 3D human corneal tissue using corneal limbal stem cells with a view to developing and commercialising novel technology has potential to transform drug discovery and regenerative medicine.
Biometric and corneal topographic characteristics in patients with Weill-Marchesani syndrome
The LISA lens
A genetic link between cats and humans for two forms of retinitis pigmentosa (RP) have been identified by a University of Missouri researcher.
A study by the Royal National Institute of Blind People (RNIB) on the prevalence and costs of sight loss estimates that 1.8 million people with partial sight and blindness lived in the UK in 2008.
Positive twelve-month primary analysis results from the Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) in patients with wet age-related macular degeneration (wet AMD) have been announced by QLT Inc.
Researchers at the University of Sydney have reported findings that support evidence of an association between retinal microvascular signs and stroke.
In a dry eye Phase II clinical trial EyeGate Pharma reports that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES).